Cargando…
Cyclosporine A and COVID19 – The COQUIMA cohort – Author's reply
Autores principales: | Guisado-Vasco, Pablo, Carnevali-Ruiz, Daniel, Vasallo, Israel John Thuissard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758177/ https://www.ncbi.nlm.nih.gov/pubmed/33392487 http://dx.doi.org/10.1016/j.eclinm.2020.100682 |
Ejemplares similares
-
Cyclosporine A and COVID-19 – The COQUIMA cohort
por: Schuurmans, Macé M., et al.
Publicado: (2020) -
Cyclosporine A and COVID19 – The COQUIMA cohort
por: Sánchez-Pernaute, Olga
Publicado: (2020) -
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)
por: Guisado-Vasco, Pablo, et al.
Publicado: (2020) -
COVID-19 and Metabolic Syndrome: NF-κB Activation. Crossroads
por: Guisado-Vasco, Pablo, et al.
Publicado: (2020) -
The Author Replies
por: Coyne, Daniel W.
Publicado: (2017)